CollPlant Biotechnologies Ltd.
CLGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $0 |
| % Growth | -57% | -91.3% | 1,153% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | -$0 | -$0 | $2 | -$0 |
| % Margin | -539% | -131.8% | 79% | -213.4% |
| R&D Expenses | $2 | $2 | $2 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $4 |
| Operating Income | -$4 | -$3 | -$2 | -$4 |
| % Margin | -4,554.5% | -1,775.4% | -80.2% | -2,423.2% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$3 | -$3 | -$1 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$3 | -$1 | -$4 |
| % Margin | -4,523.4% | -1,869.8% | -70.7% | -2,364.6% |
| EPS | -0.27 | -0.28 | -0.13 | -0.34 |
| % Growth | 3.6% | -115.4% | 61.8% | – |
| EPS Diluted | -0.27 | -0.28 | -0.13 | -0.34 |
| Weighted Avg Shares Out | 13 | 12 | 11 | 11 |
| Weighted Avg Shares Out Dil | 13 | 12 | 11 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$3 | -$1 | -$4 |
| % Margin | -4,233.8% | -1,647.5% | -58.8% | -2,217.1% |